Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:8923
Name skin melanoma
Definition A skin cancer that has_material_basis_in melanocytes.
Source DiseaseOntology.org
Alt Ids DOID:10043 DOID:10051 DOID:0050609 DOID:10046 DOID:10052 DOID:10055 DOID:8922
Path disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin melanoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Ganetespib skin melanoma sensitive detail...
BRAF V600K Dabrafenib skin melanoma sensitive detail...
BRAF V600X Dabrafenib skin melanoma sensitive detail...
BRAF V600X Vemurafenib skin melanoma sensitive detail...
KIT act mut Imatinib skin melanoma sensitive detail...
NRAS mutant Binimetinib skin melanoma sensitive detail...
BRAF V600K Vemurafenib skin melanoma sensitive detail...
BRAF V600E Dabrafenib skin melanoma sensitive detail...
BRAF V600E Vemurafenib skin melanoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib skin melanoma sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600E Binimetinib + Encorafenib skin melanoma sensitive detail...
BRAF V600E/K Vemurafenib skin melanoma sensitive detail...
BRAF V600E/K Binimetinib + Encorafenib skin melanoma sensitive detail...
BRAF V600K Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600K Dabrafenib + Trametinib skin melanoma sensitive detail...
BRAF V600K Binimetinib + Encorafenib skin melanoma sensitive detail...
BRAF V600X Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600X Dabrafenib + Trametinib skin melanoma sensitive detail...
BRAF V600X Binimetinib + Encorafenib skin melanoma sensitive detail...
BRAF V600E CDKN2A R80* Dabrafenib + Trametinib skin melanoma predicted - sensitive detail...
CDKN2A mutant N/A skin melanoma not applicable detail...
PTEN mutant N/A skin melanoma not applicable detail...
BRAF V600E Trametinib + YM-254890 skin melanoma no benefit detail...
BRAF V600E YM-254890 skin melanoma no benefit detail...
BRAF V600X Atezolizumab + Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600X Dabrafenib + Pembrolizumab + Trametinib skin melanoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01107665 Phase II Paclitaxel + Pazopanib Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma Completed USA 0
NCT01693068 Phase II Dacarbazine Pimasertib Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma Completed USA 13
NCT02203604 Phase II Aldesleukin + Ipilimumab High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Completed USA 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA 1
NCT02535078 Phase Ib/II Durvalumab Tebentafusp Tremelimumab Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma Active, not recruiting USA | CAN 4
NCT02581930 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma Active, not recruiting USA 0
NCT02680184 Phase I Pembrolizumab + QbG10 Clinical Study of CMP-001 in Combination With Pembrolizumab Active, not recruiting USA 0
NCT02731729 Phase II Ipilimumab Nivolumab Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy Completed USA 0
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Active, not recruiting USA 0
NCT02818023 Phase I Cobimetinib + Pembrolizumab + Vemurafenib Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Active, not recruiting USA 0
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Completed 2
NCT03084640 Phase Ib/II Pembrolizumab + QbG10 Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma Active, not recruiting USA 0
NCT03089606 Phase II Pembrolizumab Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker Active, not recruiting USA 0
NCT03235245 Phase II Binimetinib + Encorafenib Ipilimumab + Nivolumab Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) Recruiting 8
NCT03278665 Phase Ib/II Domatinostat + Pembrolizumab 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE) Recruiting 2
NCT03405155 Phase II Nivolumab Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery Active, not recruiting USA 0
NCT03551626 Phase III Dabrafenib + Trametinib Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus) Completed CAN 22
NCT03553836 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) Active, not recruiting USA | CAN 14
NCT03618641 Phase II Nivolumab + QbG10 CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease Completed USA 0
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed USA | CAN 1
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Recruiting USA 5
NCT03754179 Phase Ib/II Dabrafenib + Hydroxychloroquine + Trametinib Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2) Recruiting 1
NCT03817125 Phase I Nivolumab + SER-401 Vancomycin Nivolumab Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) Active, not recruiting USA 0
NCT03842943 Phase II Pembrolizumab + Talimogene laherparepvec Neoadjuvant Combination Immunotherapy for Stage III Melanoma Recruiting USA 0
NCT03864042 Phase I Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Recruiting USA | CAN 3
NCT03875079 Phase I Pembrolizumab + RO6874281 A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma Active, not recruiting USA | CAN 5
NCT03897881 Phase II mRNA-4157 + Pembrolizumab Pembrolizumab An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) Recruiting USA 1
NCT03898908 Phase II Binimetinib + Encorafenib Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL) Recruiting 1
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting USA 1
NCT03972046 Phase II Dabrafenib + Talimogene laherparepvec + Trametinib Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Withdrawn USA 0
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Active, not recruiting USA 0
NCT04007588 Phase II Ipilimumab + Nivolumab Nivolumab BMS-986205 + Nivolumab A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Withdrawn USA 0
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Recruiting USA 4
NCT04042506 Phase II Nivolumab SBRT as a Vaccination for Metastatic Melanoma Withdrawn USA 0
NCT04074096 Phase II Binimetinib + Encorafenib + Pembrolizumab Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) Not yet recruiting 1
NCT04099251 Phase III Nivolumab Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) Active, not recruiting USA | CAN 18
NCT04135352 Phase I Pembrolizumab + V938 A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) Recruiting USA | CAN 1
NCT04136834 Phase I Pegtomarginase A Phase I Open-label Study for Subjects With Advanced Malignancies (PT01) Recruiting USA 0
NCT04139902 Phase II Dostarlimab-gxly + TSR-022 Dostarlimab-gxly PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) Recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04261439 Phase I NIZ985 NIZ985 + Spartalizumab A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab Recruiting USA 6
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Recruiting 5
NCT04356729 Phase II Atezolizumab + Bevacizumab A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma Recruiting USA 0
NCT04375527 Phase II Binimetinib + Nivolumab Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Recruiting USA 0
NCT04401995 Phase II Nivolumab Nivolumab + QbG10 Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab Recruiting USA 0
NCT04410445 Phase III Nivolumab Nivolumab + NKTR-214 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) Recruiting USA 16
NCT04493203 Phase II Axitinib + Nivolumab Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Recruiting USA 0
NCT04495010 Phase II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) Withdrawn USA 15
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04526899 Phase II Cemiplimab BNT111 BNT111 + Cemiplimab Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma Recruiting USA 3
NCT04551352 Phase I RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Recruiting USA | CAN 5
NCT04570332 Phase II BO-112 + Pembrolizumab BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203) Recruiting 1
NCT04577807 Phase II PVSRIPO + unspecified PD-1 antibody PVSRIPO PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma Recruiting USA 0
NCT04592653 Phase II ALKS 4230 + Pembrolizumab A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3) Recruiting USA 0
NCT04609566 Phase II Brentuximab vedotin + Pembrolizumab Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors Recruiting USA 0
NCT04620603 Phase Ib/II Nivolumab Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer Recruiting USA 0
NCT04657991 Phase III Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for V600E/K Positive Melanoma Recruiting USA 5
NCT04697576 Phase I Nivolumab Pembrolizumab Ipilimumab Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma Recruiting USA 0
NCT04703426 Phase II Pembrolizumab + Sargramostim Sargramostim (GM-CSF) + PD-1 Recruiting USA 0
NCT04759846 Phase I Binimetinib + Encorafenib Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma Not yet recruiting 3
NCT04835805 Phase I Atezolizumab Belvarafenib + Cobimetinib Atezolizumab + Belvarafenib + Cobimetinib A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma. Recruiting USA | CAN 4
NCT04930783 Phase I CDX-301 + Nivolumab + Poly ICLC NeoVax + CDX-301 and Nivolumab in Advanced Melanoma Not yet recruiting USA 0
NCT04958239 Phase I BI 754091 + BI 765179 BI 765179 A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Recruiting USA 2
NCT04995094 Phase II Pembrolizumab Pembrolizumab + PGG beta-glucan Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma Withdrawn USA 0
NCT05060003 Phase II Atezolizumab Atezolizumab + MTIG7192A Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection Not yet recruiting USA 0
NCT05061017 Phase II Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Recruiting USA 0
NCT05098210 Phase I NeoVax + Nivolumab + Poly ICLC Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer Not yet recruiting USA 0